Idiosyncratic Drug-Induced Liver Injury: A Clinical Update
作者： Haripriya Maddur , Naga Chalasani
DOI: 10.1007/S11894-010-0154-8
关键词: Adverse drug reaction 、 Pathology 、 Fulminant liver failure 、 Medicine 、 Genome-wide association study 、 Asymptomatic 、 Intensive care medicine 、 Drug 、 Liver injury
摘要: Drug-induced liver injury (DILI) is a rare but potentially devastating adverse drug reaction. Its presentation can range from asymptomatic elevation in biochemistries to fulminant failure. Over the past decade, clinical and research interest field of idiosyncratic DILI has been intense, several new findings have reported. In this article, we provide an update on implicated agents, features, outcomes, results recently reported genetic studies.
springer.com
sci-hub.se 参考文章(34)
Criteria of drug-induced liver disorders. Report of an international consensus meeting. Journal of Hepatology. ,vol. 11, pp. 272- 276 ,(1990) , 10.1016/0168-8278(90)90124-A
E. BJÖRNSSON, E. KALAITZAKIS, R. OLSSON, The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Alimentary Pharmacology & Therapeutics. ,vol. 25, pp. 1411- 1421 ,(2007) , 10.1111/J.1365-2036.2007.03330.X
Naga Chalasani, Hisham Aljadhey, Joe Kesterson, Michael D. Murray, Stephen D. Hall, Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity Gastroenterology. ,vol. 126, pp. 1287- 1292 ,(2004) , 10.1053/J.GASTRO.2004.02.015
Craig Lammert, Stefan Einarsson, Chandan Saha, Anna Niklasson, Einar Bjornsson, Naga Chalasani, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. ,vol. 47, pp. 2003- 2009 ,(2008) , 10.1002/HEP.22272
E BJORNSSON, Drug-induced liver injury: Hy's rule revisited Clinical Pharmacology & Therapeutics. ,vol. 79, pp. 521- 528 ,(2006) , 10.1016/J.CLPT.2006.02.012
Jeffrey D. Browning, Statins and hepatic steatosis: Perspectives from the Dallas Heart Study† Hepatology. ,vol. 44, pp. 466- 471 ,(2006) , 10.1002/HEP.21248
R ANDRADE, M LUCENA, M FERNANDEZ, G PELAEZ, K PACHKORIA, E GARCIARUIZ, B GARCIAMUNOZ, R GONZALEZGRANDE, A PIZARRO, J DURAN, Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period Gastroenterology. ,vol. 129, pp. 512- 521 ,(2005) , 10.1016/J.GASTRO.2005.05.006
Ann K Daly, , Peter T Donaldson, Pallav Bhatnagar, Yufeng Shen, Itsik Pe'er, Aris Floratos, Mark J Daly, David B Goldstein, Sally John, Matthew R Nelson, Julia Graham, B Kevin Park, John F Dillon, William Bernal, Heather J Cordell, Munir Pirmohamed, Guruprasad P Aithal, Christopher P Day, , HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nature Genetics. ,vol. 41, pp. 816- 819 ,(2009) , 10.1038/NG.379
Joel R. Lim, Philip R. Faught, Naga P. Chalasani, Jean P. Molleston, Severe liver injury after initiating therapy with atomoxetine in two children. The Journal of Pediatrics. ,vol. 148, pp. 831- 834 ,(2006) , 10.1016/J.JPEDS.2006.01.035
Craig Lammert, Einar Bjornsson, Anna Niklasson, Naga Chalasani, Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events Hepatology. ,vol. 51, pp. 615- 620 ,(2010) , 10.1002/HEP.23317